Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | lamin A/C | Starlite/ChEMBL | No references |
Homo sapiens | nuclear factor, erythroid 2-like 2 | Starlite/ChEMBL | No references |
Homo sapiens | GNAS complex locus | Starlite/ChEMBL | No references |
Homo sapiens | prion protein | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | GTP-binding protein alpha subunit gna | GNAS complex locus | 394 aa | 450 aa | 28.7 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.0032 | 0.4253 | 0.4253 |
Echinococcus granulosus | lamin dm0 | 0.0033 | 0.44 | 0.4263 |
Schistosoma mansoni | transcription factor LCR-F1 | 0.0043 | 0.7087 | 0.4799 |
Onchocerca volvulus | 0.0033 | 0.44 | 0.5 | |
Loa Loa (eye worm) | hypothetical protein | 0.0016 | 0.0238 | 0.0238 |
Echinococcus multilocularis | lamin dm0 | 0.0033 | 0.44 | 0.4263 |
Echinococcus granulosus | intermediate filament protein | 0.0033 | 0.44 | 0.4263 |
Loa Loa (eye worm) | hypothetical protein | 0.0033 | 0.44 | 0.44 |
Echinococcus multilocularis | lamin | 0.0033 | 0.44 | 0.4263 |
Echinococcus multilocularis | musashi | 0.0033 | 0.44 | 0.4263 |
Mycobacterium ulcerans | cytochrome P450 185A4 Cyp185A4 | 0.0015 | 0 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.7087 | 0.5 |
Loa Loa (eye worm) | intermediate filament tail domain-containing protein | 0.0033 | 0.44 | 0.44 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0043 | 0.7087 | 0.7016 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 1 | 1 |
Loa Loa (eye worm) | intermediate filament protein | 0.0033 | 0.44 | 0.44 |
Trypanosoma cruzi | cytochrome P450, putative | 0.0015 | 0 | 0.5 |
Leishmania major | cytochrome p450-like protein | 0.0015 | 0 | 0.5 |
Trypanosoma brucei | cytochrome P450, putative | 0.0015 | 0 | 0.5 |
Brugia malayi | Intermediate filament tail domain containing protein | 0.0033 | 0.44 | 0.44 |
Brugia malayi | cytoplasmic intermediate filament protein | 0.0017 | 0.0665 | 0.0665 |
Brugia malayi | hypothetical protein | 0.0043 | 0.7087 | 0.7087 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0043 | 0.7087 | 0.7016 |
Echinococcus granulosus | lamin | 0.0033 | 0.44 | 0.4263 |
Schistosoma mansoni | hypothetical protein | 0.0043 | 0.7087 | 0.4799 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.7087 | 0.5 |
Brugia malayi | intermediate filament protein | 0.0033 | 0.44 | 0.44 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 1 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.7087 | 0.5 |
Loa Loa (eye worm) | cytoplasmic intermediate filament protein | 0.0017 | 0.0665 | 0.0665 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 1 | 1 |
Onchocerca volvulus | 0.0033 | 0.44 | 0.5 | |
Loa Loa (eye worm) | hypothetical protein | 0.0015 | 0.0091 | 0.0091 |
Loa Loa (eye worm) | hypothetical protein | 0.0015 | 0.0091 | 0.0091 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 1 | 1 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 1 | 1 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0055 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450, putative | 0.0015 | 0 | 0.5 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 1 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.7087 | 0.5 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | 8.38 uM | PubChem BioAssay. TRFRET-based cell-based high throughput dose response assay to identify inhibitors of cell surface Prion Protein (PRPC). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 5.0119 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 5.8048 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Potency (functional) | 8.2753 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | = 19.9526 um | PUBCHEM_BIOASSAY: qHTS Assay for Modulators of Lamin A Splicing. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent). (Class of assay: confirmatory) [Related pubchem assays: 2158 (Confirmation qHTS Assay for Inhibitors of Cruzain), 2249 (Probe Development Summary of Promiscuous Inhibitors (Artifacts) of Cruzain), 2161 (qHTS Assay for Inhibitors of Papain: Counterscreen for Cruzain Assay), 1478 (qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent))] | ChEMBL. | No reference |
Potency (functional) | 79.4328 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of BAZ2B. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504391] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.